Latest from Yale Cancer Center

Patients with stage III colon cancer who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.
People with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don
Mario Sznol, MD, discusses overall advances in the field of melanoma, as well as novel treatments with the potential to change the treatment paradigm.
Harriet Kluger, MD, professor of medicine, associate cancer center director for education and training, deputy section chief, Medical Oncology, Yale Cancer Center, discusses the progression of treatment for patients with melanoma who have brain metastases.
Adding ramucirumab to standard first-line chemotherapy significantly improved investigator-assessed progression-free survival compared with chemotherapy plus placebo in treatment-naive patients with HER2-negative gastric cancer.
Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the role of surgery in the treatment of patients with melanoma.
 
Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer
 
Ramucirumab (Cyramza) plus docetaxel improved progression-free survival over docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.
Publication Bottom Border
Border Publication
x